GlassScriptPhysician profile
Nirgiz Taha
NPI 1619511540
$2,443.78
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $690 · 2023: $577 · 2024: $588 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $797.26 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $301.84 | 2021-2024 | Xarelto |
| Pfizer INC. | $237.55 | 2021-2025 | |
| Chiesi USA, INC. | $184.42 | 2021-2022 | |
| Amgen INC. | $183.45 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $179.91 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.53 | 2021-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $105.67 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $49.69 | 2022-2025 | Evkeeza |
| Medicomp INC | $48.98 | 2025 | Telepatch Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.38 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $21.79 | 2023 | |
| Heartflow, INC. | $18.75 | 2024 | |
| Inspire Medical Systems, INC. | $18.74 | 2025 | Inspire |
| Boston Scientific Corporation | $18.72 | 2024 | Bodyguardian |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.60 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $17.02 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $14.06 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $13.93 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $11.90 | 2022 | |
| Shockwave Medical, INC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirgiz Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.